Summary
77.84 -0.26(-0.33%)10/15/2024
Astrazeneca plc (AZN)
Astrazeneca plc (AZN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.35 | 1.28 | -1.53 | -0.28 | 13.25 | 14.77 | 94.50 | 4,297.74 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 77.84 | |
| Open | 77.68 | |
| High | 78.13 | |
| Low | 77.42 | |
| Volume | 2,299,795 | |
| Change | -0.27 | |
| Change % | -0.35 | |
| Avg Volume (20 Days) | 2,926,227 | |
| Volume/Avg Volume (20 Days) Ratio | 0.79 | |
| 52 Week Range | 60.47 - 87.67 | |
| Price vs 52 Week High | -11.21% | |
| Price vs 52 Week Low | 28.72% | |
| Range | 0.21 | |
| Gap Up/Down | -0.63 | |
Fundamentals | ||
| Market Capitalization (Mln) | 242,403 | |
| EBIDTA | 15,802,999,808 | |
| PE Ratio | 38.2079 | |
| PEG Ratio | 0.8861 | |
| WallStreet Target Price | 82.74 | |
| Book Value | 24.1740 | |
| Earnings Per Share | 2.0200 | |
| EPS Estimate Current Quarter | 1.2200 | |
| EPS Estimate Next Quarter | 1.3200 | |
| EPS Estimate Current Year | 4.0600 | |
| EPS Estimate Next Year | 5.7200 | |
| Diluted EPS (TTM) | 2.0200 | |
| Revenues | ||
| Profit Marging | 0.1330 | |
| Operating Marging (TTM) | 0.2611 | |
| Return on asset (TTM) | 0.0704 | |
| Return on equity (TTM) | 0.1729 | |
| Revenue TTM | 47,610,998,784 | |
| Revenue per share TTM | 2.5512 | |
| Quarterly Revenue Growth (YOY) | 0.1650 | |
| Quarterly Earnings Growth (YOY) | 0.2070 | |
| Gross Profit (TTM) | 35,732,000,000 | |
| Dividends | ||
| Dividend Share | 2.9000 | |
| Dividend Yield | 0.0188 | |
| Valuations | ||
| Trailing PE | 38.2079 | |
| Forward PE | 16.3132 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.4598 | |
| Revenue Enterprise Value | 5.1971 | |
| EBITDA Enterprise Value | 17.7384 | |
| Shares | ||
| Shares Outstanding | 3,100,470,016 | |
| Shares Float | 1,543,222,230 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.01 | |
| Institutions (%) | 16.86 | |
10/14 12:41 EST - zacks.com
AZN or NVO: Which Is the Better Value Stock Right Now?
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Astrazeneca (AZN) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?
AZN or NVO: Which Is the Better Value Stock Right Now?
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Astrazeneca (AZN) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?
10/09 10:35 EST - zacks.com
Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Astrazeneca (AZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Astrazeneca (AZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
10/09 09:47 EST - proactiveinvestors.co.uk
UK bosses get green light to hike pay from investment body
Britain's bosses have been given the green light to pay themselves more by their institutional owners Institutional trade body the Investment Association made the call in a new set of guidelines issued today designed to halt a brain drain of top management talent to better-paid jobs in the US. After years of its members hectoring bosses over pay, the IA now says it will introduce principles to enable them to vote through large awards without breaching any guidelines.
UK bosses get green light to hike pay from investment body
Britain's bosses have been given the green light to pay themselves more by their institutional owners Institutional trade body the Investment Association made the call in a new set of guidelines issued today designed to halt a brain drain of top management talent to better-paid jobs in the US. After years of its members hectoring bosses over pay, the IA now says it will introduce principles to enable them to vote through large awards without breaching any guidelines.
10/08 14:05 EST - zacks.com
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases.
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases.
10/08 06:30 EST - fool.com
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
Investing in the most popular players in the space isn't the only valid approach.
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
Investing in the most popular players in the space isn't the only valid approach.
10/08 05:05 EST - zacks.com
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.
10/07 12:44 EST - 247wallst.com
Like Him Or Hate Him, George Soros Is Betting Big On These 3 Stocks You Should Be Watching
George Soros is among the most renowned and controversial hedge fund managers on the planet.
Like Him Or Hate Him, George Soros Is Betting Big On These 3 Stocks You Should Be Watching
George Soros is among the most renowned and controversial hedge fund managers on the planet.
10/07 11:00 EST - zacks.com
5 Large Drug Stocks to Watch From a Thriving Industry
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.
5 Large Drug Stocks to Watch From a Thriving Industry
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.
10/07 10:51 EST - gurufocus.com
AstraZeneca Collaborates with CSPC to Develop Innovative Lp(a) Inhibitor
AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group to advance the development of a novel preclinical small molecule lipoprotein(a) (Lp(a)) inhibitor.
AstraZeneca Collaborates with CSPC to Develop Innovative Lp(a) Inhibitor
AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group to advance the development of a novel preclinical small molecule lipoprotein(a) (Lp(a)) inhibitor.
10/07 07:52 EST - proactiveinvestors.co.uk
AstraZeneca buys licence for cholesterol treatment from China's CSPC
AstraZeneca PLC (LSE:AZN) shares got a small boost as the UK's largest pharma company snapped up a licence for a drug that could lower in the bloodstream, paying $100 million initially. The FTSE 100 group struck an exclusive license deal for a pre-clinical novel molecule that has shown it can prevent the formation of types of particles that carry cholesterol in the bloodstream, known as lipoproteins, which are a combination of fat and protein.
AstraZeneca buys licence for cholesterol treatment from China's CSPC
AstraZeneca PLC (LSE:AZN) shares got a small boost as the UK's largest pharma company snapped up a licence for a drug that could lower in the bloodstream, paying $100 million initially. The FTSE 100 group struck an exclusive license deal for a pre-clinical novel molecule that has shown it can prevent the formation of types of particles that carry cholesterol in the bloodstream, known as lipoproteins, which are a combination of fat and protein.
10/07 04:58 EST - marketwatch.com
AstraZeneca to pay up to $2 billion to license cardiovascular drug
AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.
AstraZeneca to pay up to $2 billion to license cardiovascular drug
AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.
10/07 04:53 EST - reuters.com
AstraZeneca in $1.9 bln licensing deal with HK-listed CSPC
AstraZeneca said on Monday it would pay up to $1.9 billion to CSPC Pharmaceutical Group Ltd in an exclusive license agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline.
AstraZeneca in $1.9 bln licensing deal with HK-listed CSPC
AstraZeneca said on Monday it would pay up to $1.9 billion to CSPC Pharmaceutical Group Ltd in an exclusive license agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline.
10/07 02:08 EST - globenewswire.com
Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca's inhaled anti-inflammatory medication Airsupra in asthma patients
London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating AstraZeneca's Airsupra (albuterol/budesonide) in patients with intermittent or mild persistent asthma has delivered positive results. The trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction1 in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.
Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca's inhaled anti-inflammatory medication Airsupra in asthma patients
London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating AstraZeneca's Airsupra (albuterol/budesonide) in patients with intermittent or mild persistent asthma has delivered positive results. The trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction1 in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.
10/03 12:51 EST - zacks.com
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.
10/02 16:05 EST - businesswire.com
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate casdatifan (AB521), Arcus's investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, in patients wi.
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate casdatifan (AB521), Arcus's investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, in patients wi.
10/02 03:00 EST - businesswire.com
Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer
PARIS--(BUSINESS WIRE)--Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides. As part of Owkin's ongoing collaboration with Gustave Roussy and The Centre Léon Bérard through PortrAIt, a Fre.
Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer
PARIS--(BUSINESS WIRE)--Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides. As part of Owkin's ongoing collaboration with Gustave Roussy and The Centre Léon Bérard through PortrAIt, a Fre.
10/01 13:00 EST - zacks.com
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025.
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025.
09/26 16:01 EST - zacks.com
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga are likely to drive sales. It has several candidates with blockbuster potential.
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga are likely to drive sales. It has several candidates with blockbuster potential.
09/26 13:11 EST - zacks.com
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.
09/26 10:41 EST - zacks.com
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.